Teng CM, Huang TF. Snake venom constituents that affect platelet function. Platelets. 1991;2:77–87.
Article
CAS
PubMed
Google Scholar
Clemetson KJ. Snaclecs (snake C-type lectins) that inhibit or activate platelets by binding to receptors. Toxicon. 2010;56:1236–46.
Article
CAS
PubMed
Google Scholar
Hynes RO. Integrins - versatility, modulation, and signaling in cell-adhesion. Cell. 1992;69:11–25.
Article
CAS
PubMed
Google Scholar
Ginsberg MH, Loftus JC, Plow EF. Cytoadhesins, integrins, and platelets. Thromb Haemost. 1988;59:1–6.
CAS
PubMed
Google Scholar
Watson SP, Auger JM, McCarty OJT, Pearce AC. GPVI and integrin alpha II beta 3 signaling in platelets. J Thromb Haemost. 2005;3:1752–62.
Article
CAS
PubMed
Google Scholar
Coller BS. Platelets and thrombolytic therapy. N Engl J Med. 1990;322:33–42.
Article
CAS
PubMed
Google Scholar
Huang TF, Holt JC, Lukasiewicz H, Niewiarowski S. Trigramin - a low-molecular-weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein-IIb-IIIa complex. J Biol Chem. 1987;262:16157–63.
CAS
PubMed
Google Scholar
Huang TF, Ouyang C. Action mechanism of the potent platelet-aggregation inhibitor from Trimeresurus gramineus snake venom. Thromb Res. 1984;33:125–38.
Article
CAS
PubMed
Google Scholar
Huang TF, Liu CZ, Ouyang CH, Teng CM. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist. Biochem Pharmacol. 1991;42:1209–19.
Article
CAS
PubMed
Google Scholar
Huang TF, Wu YJ, Ouyang C. Characterization of a potent platelet aggregation inhibitor from Agkistrodon rhodostoma snake venom. Biochim Biophys Acta. 1987;925:248–57.
Article
CAS
PubMed
Google Scholar
Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem. 1988;263:19827–32.
CAS
PubMed
Google Scholar
Huang TF, Holt JC, Kirby EP, Niewiarowski S. Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets. Biochemistry. 1989;28:661–6.
Article
CAS
PubMed
Google Scholar
Cook JJ, Huang TF, Rucinski B, Strzyzewski M, Tuma RF, Williams JA, et al. Inhibition of platelet hemostatic plug formation by trigramin, a novel RGD-peptide. Am J Physiol. 1989;256:H1038–43.
CAS
PubMed
Google Scholar
Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, et al. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation. 1991;83:1038–47.
Article
CAS
PubMed
Google Scholar
Rote WE, Mu DX, Roncinske RA, Frelinger 3rd AL, Lucchesi BR. Prevention of experimental carotid artery thrombosis by applaggin. J Pharmacol Exp Ther. 1993;267:809–14.
CAS
PubMed
Google Scholar
Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, et al. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991;266:9359–62.
CAS
PubMed
Google Scholar
Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem. 1993;268:1066–73.
CAS
PubMed
Google Scholar
Gould RJ, Polokoff MA, Friedman PA, Huang TF, Holt JC, Cook JJ, et al. Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med. 1990;195:168–71.
Article
CAS
PubMed
Google Scholar
Califf RM, Shadoff N, Valett N, Bates E, Galeana A, Knopf W, et al. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956–61.
Article
Google Scholar
Momic T, Katzhendler J, Shai E, Noy E, Senderowitz H, Eble JA, et al. Vipegitide: a folded peptidomimetic partial antagonist of alpha2beta1 integrin with antiplatelet aggregation activity. Drug Des Devel Ther. 2015;9:291–304.
PubMed
PubMed Central
Google Scholar
Jia LG, Wang XM, Shannon JD, Bjarnason JB, Fox JW. Function of disintegrin-like/cysteine-rich domains of atrolysin A. Inhibition of platelet aggregation by recombinant protein and peptide antagonists. J Biol Chem. 1997;272:13094–102.
Article
CAS
PubMed
Google Scholar
Knudsen KA, Tuszynski GP, Huang TF, Niewiarowski S. Trigramin, an RGD-containing peptide from snake venom, inhibits cell-substratum adhesion of human melanoma cells. Exp Cell Res. 1988;179:42–9.
Article
CAS
PubMed
Google Scholar
Sheu JR, Lin CH, Chung JL, Teng CM, Huang TF. Triflavin, an Arg-Gly-Asp-containing antiplatelet peptide inhibits cell-substratum adhesion and melanoma cell-induced lung colonization. Jpn J Cancer Res. 1992;83:885–93.
Article
CAS
PubMed
Google Scholar
Yeh CH, Peng HC, Yang RS, Huang TF. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells. Mol Pharmacol. 2001;59:1333–42.
CAS
PubMed
Google Scholar
Yeh CH, Peng HC, Huang TF. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood. 1998;92:3268–76.
CAS
PubMed
Google Scholar
Wu WB, Peng HC, Huang TF. Disintegrin causes proteolysis of beta-catenin and apoptosis of endothelial cells. Involvement of cell-cell and cell-ECM interactions in regulating cell viability. Exp Cell Res. 2003;286:115–27.
Article
CAS
PubMed
Google Scholar
Zhou Q, Sherwin RP, Parrish C, Richters V, Groshen SG, Tsao-Wei D, et al. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. Breast Cancer Res Treat. 2000;61:249–60.
Article
CAS
PubMed
Google Scholar
Momic T, Katzehendler J, Benny O, Lahiani A, Cohen G, Noy E, et al. Vimocin and vidapin, cyclic KTS peptides, are dual antagonists of alpha1beta1/alpha2beta1 integrins with antiangiogenic activity. J Pharmacol Exp Ther. 2014;350:506–19.
Article
CAS
PubMed
Google Scholar
Eisele G, Wick A, Eisele AC, Clement PM, Tonn J, Tabatabai G, et al. Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. J Neurooncol. 2014;117:141–5.
Article
CAS
PubMed
Google Scholar
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1100–8.
Article
CAS
PubMed
Google Scholar
Vansteenkiste J, Barlesi F, Waller CF, Bennouna J, Gridelli C, Goekkurt E, et al. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Ann Oncol. 2015;26:1734–40.
Article
CAS
PubMed
Google Scholar
Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam do H, et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015;17:708–17.
Article
PubMed
PubMed Central
Google Scholar
West AP, Koblansky AA, Ghosh S. Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol. 2006;22:409–37.
Article
CAS
PubMed
Google Scholar
Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev. 2003;16:379–414.
Article
PubMed
PubMed Central
Google Scholar
Gerold G, Abu Ajaj K, Bienert M, Laws HJ, Zychlinsky A, de Diego JL. A Toll-like receptor 2-integrin beta3 complex senses bacterial lipopeptides via vitronectin. Nat Immunol. 2008;9:761–8.
Article
CAS
PubMed
Google Scholar
Hsu CC, Chuang WJ, Chang CH, Tseng YL, Peng HC, Huang TF. Improvements in endotoxemic syndromes using a disintegrin, rhodostomin, through integrin alphavbeta3-dependent pathway. J Thromb Haemost. 2011;9:593–602.
Article
CAS
PubMed
Google Scholar
Hsu CC, Chuang WJ, Chung CH, Chang CH, Peng HC, Huang TF. Snake venom disintegrin inhibits the activation of toll-like receptors and alleviates sepsis through integrin alphaVbeta3 blockade. Sci Rep. 2016;6:23387.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bassand JP. Current antithrombotic agents for acute coronary syndromes: focus on bleeding risk. Int J Cardiol. 2013;163:5–18.
Article
PubMed
Google Scholar
Bougie DW, Rasmussen M, Zhu J, Aster RH. Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of alphaIIb/beta3 integrin. Blood. 2012;119:6317–25.
Article
CAS
PubMed
PubMed Central
Google Scholar
Huang TF, Chang CH, Ho PL, Chung CH. FcgammaRII mediates platelet aggregation caused by disintegrins and GPIIb/IIIa monoclonal antibody, AP2. Exp Hematol. 2008;36:1704–13.
Article
CAS
PubMed
Google Scholar
Gao C, Boylan B, Bougie D, Gill JC, Birenbaum J, Newman DK, et al. Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. J Clin Invest. 2009;119:504–11.
Article
CAS
PubMed
PubMed Central
Google Scholar
Blue R, Murcia M, Karan C, Jirouskova M, Coller BS. Application of high-throughput screening to identify a novel alphaIIb-specific small molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen. Blood. 2008;111:1248–56.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhu J, Zhu J, Negri A, Provasi D, Filizola M, Coller BS, et al. Closed headpiece of integrin alphaIIbbeta3 and its complex with an alphaIIbbeta3-specific antagonist that does not induce opening. Blood. 2010;116:5050–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shen B, Zhao X, O'Brien KA, Stojanovic-Terpo A, Delaney MK, Kim K, et al. A directional switch of integrin signalling and a new anti-thrombotic strategy. Nature. 2013;503:131–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM, et al. Talin binding to integrin beta tails: a final common step in integrin activation. Science. 2003;302:103–6.
Article
CAS
PubMed
Google Scholar
Vinogradova O, Velyvis A, Velyviene A, Hu B, Haas T, Plow E, et al. A structural mechanism of integrin alpha(IIb)beta(3) “inside-out” activation as regulated by its cytoplasmic face. Cell. 2002;110:587–97.
Article
CAS
PubMed
Google Scholar
Haling JR, Monkley SJ, Critchley DR, Petrich BG. Talin-dependent integrin activation is required for fibrin clot retraction by platelets. Blood. 2011;117:1719–22.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hsu CC, Chuang WJ, Chung CH, Chang CH, Peng HC, Huang TF. Improved antithrombotic activity and diminished bleeding side effect of a PEGylated alphaIIbbeta3 antagonist, disintegrin. Thromb Res. 2016;143:3–10.
Article
CAS
PubMed
Google Scholar